

***Aspergillus*-mediated allergic airway inflammation is triggered by dendritic cell recognition of a defined spore morphotype**



Emma L. Houlder, PhD,^{a,b} Sara Gago, PhD,^c George Vere, PhD,^d Julio Furlong-Silva, PhD,^d Daniel Conn, MSc,^d Emer Hickey, PhD,^d Saba Khan, MSc,^a Darren Thomson, PhD,^{c,d} Mark W. Shepherd, MSc,^a Ressa Lebedinec, PhD,^c Gordon D. Brown, PhD,^d William Horsnell, PhD,^d Mike Bromley, PhD,^c Andrew S. MacDonald, PhD,^a and Peter C. Cook, PhD^{a,d} *Exeter and Manchester, United Kingdom; and Leiden, The Netherlands*

Background: Exposure to fungi, especially *Aspergillus fumigatus*, can elicit potent allergic inflammation that triggers and worsens asthmatic disease. Dendritic cells (DCs) initiate allergic inflammatory responses to allergic stimuli. However, it is unclear if *Af* spores during isotropic growth (early spore swelling) can activate DCs to initiate allergic responses or if germination is required. This lack of basic understanding of how *Af* causes disease is a barrier to developing new treatments. **Objective:** We sought to show that a precise *Af* morphotype stage during spore swelling can trigger DCs to mediate allergic inflammatory responses and ascertain if antifungal therapeutics can be effective at suppressing this process.

Methods: We used an *Af* strain deficient in pyrimidine biosynthesis (Δ pyrG) to generate populations of *Af* spores arrested at different stages of isotropic growth (swelling) via temporal removal of uracil and uridine from growth media. These arrested spore stages were cultured with bone marrow-derived DCs (BMDCs), and their activation was measured via flow cytometry and ELISA to examine which growth stage was able to activate BMDCs. These BMDCs were then adoptively transferred into the airways to assess if they were able to mediate allergic inflammation in naïve recipient mice. Allergic airway inflammation *in vivo* was determined via flow cytometry, ELISA, and real-time quantitative PCR. This system was also used to determine if antifungal drug (itraconazole) treatment could alter early stages of spore swelling and therefore BMDC activation and *in vivo* allergic inflammation upon adoptive transfer.

Results: We found that *Af* isotropic growth is essential to trigger BMDC activation and mediate allergic airway inflammation. Furthermore, using time-arrested *Af* stages, we found that at

least 3 hours in growth media enabled spores to swell sufficiently to activate BMDCs to elicit allergic airway inflammation *in vivo*. Incubation of germinating *Af* with itraconazole reduced spore swelling and partially reduced their ability to activate BMDCs to elicit *in vivo* allergic airway inflammation.

Conclusion: Our results have pinpointed the precise stage of *Af* development when germinating spores are able to activate DCs to mediate downstream allergic airway inflammation. Furthermore, we have identified that antifungal therapeutics partially reduced the potential of *Af* spores to stimulate allergic responses, highlighting a potential mechanism by which antifungal treatment might help prevent the development of fungal allergy. (J Allergy Clin Immunol 2025;155:988-1001.)

Key words: *Aspergillus fumigatus*, fungal asthma, dendritic cells, asthma, allergic airway inflammation, itraconazole, antifungal

Fungi are abundant in the environment, with a diverse range of fungal species (including *Aspergillus fumigatus*, *Candida albicans*, and *Alternaria alternata*) known to be major drivers of asthma.¹⁻⁴ At least 10 million people worldwide display significant sensitivity to *Af*, which increases asthma severity⁵ and can lead to the development of debilitating chronic fungal infections^{6,7} such as allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization.⁸ Despite the significant clinical burden of these diseases, treatment options are limited. Moreover, there is much debate on whether it is preferable to administer therapeutics, such as corticosteroids, that dampen the underlying allergic inflammation but may interfere with antifungal immunity⁹ or to utilize antifungal therapies, such as the drug itraconazole, which have been shown to improve health for individuals with chronic allergic fungal conditions.^{10,11} Although the precise mechanisms that might explain how such treatments are effective are unknown, these observations suggest that *Af* plays a critical, yet underappreciated, role in mediating responses that underpin allergic airway inflammation.

The immune events that cause individuals to become sensitized to *Af* spores and develop allergic airway inflammatory disease is unclear. In healthy settings, the majority of spores are removed in the upper airways, with their small size (2-3 μ m) allowing around 20% of inhaled *Af* spores to reach the alveoli, where they are thought to be cleared by cells of the epithelial barrier, along with innate immune cells such as macrophages and dendritic cells (DCs).¹²⁻¹⁵ However, relatively few studies have focused on whether *Af* spores activate these cells to coordinate allergic inflammatory responses. In the lung, DCs sample the airway and

From ^athe Lydia Becker Institute of Immunology and Inflammation, University of Manchester, Manchester; ^bthe Leiden University Center for Infectious Disease, Leiden University Medical Centre, Leiden; ^cthe Manchester Fungal Infection Group, Division of Evolution, Infection, and Genomics, Faculty of Biology, Medicine, and Health, University of Manchester, Manchester; and ^dthe Department of Biosciences, Medical Research Council Centre for Medical Mycology at the University of Exeter, Faculty of Health and Life Sciences, Exeter.

Received for publication March 6, 2024; revised October 26, 2024; accepted for publication October 31, 2024.

Available online November 23, 2024.

Corresponding author: Peter C. Cook, PhD, Department of Biosciences, Medical Research Centre for Medical Mycology at the University of Exeter, Faculty of Health and Life Sciences, Exeter, United Kingdom. E-mail: p.c.cook@exeter.ac.uk.

The CrossMark symbol notifies online readers when updates have been made to this article such as errata or minor corrections

0091-6749

© 2024 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

<https://doi.org/10.1016/j.jaci.2024.10.040>

Abbreviations used

BAL:	Bronchoalveolar lavage
BMDC:	Bone marrow–derived DC
cDC1/2:	Conventional cell type 1/2
DC:	Dendritic cell
EDTA:	Ethylenediaminetetraacetic acid
FACS:	Fluorescence-activated cell sorting
FBS:	Fetal bovine serum
GM-CSF:	Granulocyte-macrophage colony-stimulating factor
LPS:	Lipopolysaccharide
MHC-II:	Major histocompatibility complex class II
PBS:	Phosphate-buffered saline
PFA:	Paraformaldehyde
PMA:	Phorbol 12-myristate 13-acetate
qPCR:	Real-time quantitative PCR
RELMA:	Resistin-like molecule alpha
u/u:	Uridine and uracil
WT:	Wild type

migrate to the draining lymph nodes to mediate antigen-specific T-cell responses against a range of stimuli, including fungi.^{16–18} We have recently identified that DCs orchestrate CD4⁺ T-cell responses to repeated exposures of *Af* spores to generate a mixed type 2 (eosinophilia with IL-4, IL-5, and IL-13) and type 17 (neutrophilia with IL-17) inflammatory cytokine environment.¹⁹ These immune changes mediate the hallmark symptoms of asthma, including airway hypersensitivity, luminal narrowing, smooth muscle hyperplasia, and mucus overproduction.²⁰ In contrast to other allergens, such as house dust mite, little is known about whether *Af* spores actively reveal factors that trigger DC-mediated sensitization to promote fungal allergic airway inflammatory disease.

If not rapidly cleared from the airways, within hours, *Af* spores can undergo morphogenetic changes as they swell and then germinate to form hyphae.^{21,22} Resting *Af* spores are coated in an immunologically inert dense α -1,3-glucan, melanin, and rodlet hydrophobin layer.^{23–28} This layer is shed as spores break dormancy and undergo isotropic growth (swelling),²³ exposing pathogen-associated molecular patterns, such as carbohydrate motifs including β -1,3-glucan, that can be recognized by innate immune cells and trigger potent inflammatory responses.^{28–31} Furthermore, numerous *Af* allergens have been identified, with hyphal proteases (Asp f 5, Alp1, and Asp f 13) particularly implicated in mediating allergic inflammatory responses.^{32–35} However, whether these allergens are expressed in early germinating spores and mediate initial sensitization via DCs is unknown. Deeper understanding of the potential immunogenicity of molecules exposed on the swollen spores³⁶ is vital to precisely map when *Af* spores develop allergenic properties and to identify how this process may be therapeutically manipulated.³⁷

In this study, we have demonstrated a requirement for *Af* spore swelling to induce immune activation, both *in vitro* and *in vivo*, with a particular focus on DCs because of their crucial role in directing allergic airway inflammation. Further, we have identified the stage in *Af* isotropic growth at which spores are able to activate bone marrow–derived DCs (BMDCs) to initiate allergic airway inflammation in female mice. Finally, we have shown that

treatment with the antifungal itraconazole can partially reduce the allergenicity of *Af* spores, and therefore their capacity to activate BMDCs to initiate allergic airway inflammation. These results not only precisely define the development of allergenicity during *Af* spore swelling but also provide mechanistic evidence to explain the therapeutic benefit of antifungal treatment in allergic airway inflammation.

METHODS

Aspergillus strains and culture

Af A1160 Δ pyrG (*pyrG*[−]) was used to generate stage-arrested *Af* spores, while A1160 *pyrG*⁺ (referred to as A1160 wild type) strain was used as control for comparisons for *in vitro* and *in vivo* *Af* challenge.^{38–40} The A1160 strain was derived from CEA10, an invasive aspergillosis clinical isolate.⁴¹ In experiments involving DC transfer to recipient mice, mice were challenged with spores of the parental CEA10 strain. *Af* was grown on Sabouraud dextrose agar (Oxoid) at 37°C supplemented with 5 mmol uridine and 5 mmol uracil (u/u, both Sigma) for the A1160 Δ pyrG strain. Spores were collected and resuspended in RPMI 1640 (Sigma) at 1.6×10^7 spores/mL in the presence or absence of 5 mmol u/u. In some experiments, these were further supplemented with 2 μ g/mL itraconazole (Thermo Fisher Scientific). Stage-arrested spores were generated by incubation at 37°C (with shaking) for defined periods and washed in nonsupplemented RPMI 1640 (Gibco; Thermo Fisher Scientific) to remove excess u/u. To aid counting, spores were sonicated for 3 seconds at 20% amplitude to disperse clumps. Swollen spores were stored in nonsupplemented RPMI 1640 at 4°C for up to 24 hours before addition to BMDC culture or assessed directly by flow cytometry.

BMDC culture

BMDCs were generated with granulocyte-macrophage colony-stimulating factor (GM-CSF) as previously described.⁴⁰ In brief, 2×10^5 bone marrow cells were seeded in complete medium (RPMI 1640 [Sigma] containing 20 ng/mL GM-CSF [Pepro-Tech], 10% fetal calf serum (Sigma), 2 mmol L-glutamine (Gibco), 50 U/mL penicillin, and 50 μ g/mL streptomycin (Life Technologies; Thermo Fisher Scientific). Cells were cultured at 37°C in a humidified atmosphere of 5% CO₂. On day 3, 10 mL of complete medium was added, and on days 6 and 8, 9 mL of media was gently aspirated and replaced with 10 mL of fresh complete medium. After 10 days of culture, BMDCs were collected and replated at 2×10^6 cells/mL for further assays. *Af* spores were added to BMDCs at multiplicity of infection 5:1 and incubated for 5 hours at 37°C in a humidified atmosphere of 5% CO₂ in complete medium with 5 ng/mL GM-CSF. Media or 250 ng/mL lipopolysaccharide (LPS; Sigma) was added as negative and positive controls, respectively.

Murine models

C57BL/6 (Envigo) mice were maintained under specific pathogen-free conditions at the University of Manchester (licence P44492AC9) or the University of Exeter (licence P6A6F95B5 or PP6094315). All animal studies were ethically reviewed and carried out in accordance with the Animals (Scientific

Procedures) Act of 1986 and the GSK Policy on the Care, Welfare, and Treatment of Animals. Female mice aged 6 to 17 weeks were used for analysis. No *a priori* sample size calculations were performed to determine number of mice used per group. All mice were included in the analysis, with no exclusions. For statistical calculations, individual mice were regarded as the experimental unit. Blinding and randomization of treatment groups was not performed. To account for confounding cage effects, mice from different treatment groups were cohoused.

In repeat *Af* exposure models, experimental mice were exposed intranasally to 4×10^5 *Af* spores (A1160) in 30 μ L phosphate-buffered saline (PBS) 0.05% Tween or vehicle control on days 0, 2, 4, 7, 9, and 11. Mice were humanely killed at day 12 after the first *Af* dose. In DC transfer models, mice were sensitized via intranasal transfer of 5×10^4 BMDCs (day 0), challenged with *Af* (CEA10) on days 12 and 13 after transfer (4×10^5 each day), and humanely killed on day 14.

Cell isolation

For analysis of cellular changes *in vivo*, cells were isolated from the bronchiolar lavage (BAL) sample, lung tissue, and mediastinal lymph nodes. BAL samples were collected by washing the lungs with PBS containing 2% fetal bovine serum (FBS) and 2 mmol ethylenediaminetetraacetic acid (EDTA; Sigma). Lungs were processed via incubation at 37°C with 0.8 U/mL Liberase TL (Sigma) and 80 U/mL DNase I type IV (Sigma) in Hanks balanced salt solution (Gibco), as previously described.⁴⁰ After 40 minutes, digestion was halted with PBS containing 2% FBS and 2 mmol EDTA, and the suspension was passed through a 70 μ m cell strainer. Red blood cells were lysed using a red blood cell lysis buffer (Sigma). To assess cytokine secretion potential, lung cells were stimulated *ex vivo* for 3 hours at 37°C with 20 ng/mL phorbol 12-myristate 13-acetate (PMA; Sigma) and 1 μ L/mL GolgiStop (Becton Dickinson [BD]) in X-vivo-15 (Lonza) supplemented with 1% L-glutamine (Gibco) and 0.1% β -mercaptoethanol (Sigma). Cultures were carried out in 96-well round-bottomed plates, with 4×10^5 cells per well in 200 μ L final volume.

Flow cytometry

Isolated cell suspensions were washed with PBS and stained for viability with ZombieUV (1:2000; BioLegend). Samples were then blocked with 5 μ g/mL α CD16/CD32 (2.4G2; BioLegend) in fluorescence-activated cell sorting (FACS) buffer (PBS containing 2% FBS and 2 mmol EDTA) before staining for surface markers at 4°C for 30 minutes. After staining, cells were washed twice in FACS buffer and then fixed in 1% paraformaldehyde (PFA) in PBS for 10 minutes at room temperature. For detection of intracellular antigens, cells were fixed with BD Cytofix/Cytoperm (BD) for 1 hour. Cells were then washed 3 times with eBioscience (Thermo Fisher Scientific) permeabilization buffer before overnight staining with intracellular cytokine antibodies in eBioscience permeabilization buffer. Samples were acquired on a BD Fortessa device with FACSDiva (BD) software and analyzed by FlowJo v10 (Treestar). Gating was informed by the use of fluorescence-minus-1 controls. Flow cytometry gating schemes are shown in Figs E1–E3 in this article's Online Repository available at www.jacionline.org. Antibodies used are listed in Table E1, also in the Online Repository.

ELISA

Enzyme-linked immunosorbent assays (ELISAs) were performed on BAL and BMDC culture supernatants using paired monoclonal antibodies and recombinant cytokine standards, or DuoSets following the manufacturer's instructions (BioLegend, R&D Systems, and PeproTech). A list of the antibodies used is provided in Table E2 in the Online Repository available at www.jacionline.org.

RNA extraction and qPCR gene expression

Lung tissue was collected in RNeasy lysis buffer (Thermo Fisher Scientific) for storage at -80°C before subsequent processing. Once thawed, tissues were homogenized in RLT lysis buffer in a Geno/Grinder (SPEX) and RNA isolated using RNeasy columns (Qiagen) following the manufacturer's instructions. Complementary DNA was generated from extracted RNA using SuperScript-III and Oligo-dT (Thermo Fisher Scientific). Relative quantification of genes of interest was performed by real-time quantitative PCR (qPCR) analysis using the QuantStudio Pro 7 system (Thermo Fisher Scientific) and SYBR Green Master Mix (Thermo Fisher Scientific), compared to a serially diluted standard of pooled cDNA. Expression was normalized to GAPDH.¹⁹ Primers used are listed in Table E3 in the Online Repository available at www.jacionline.org.

Histologic staining

Lungs were collected into 10% neutral buffered formalin (Sigma), fixed overnight, and washed and stored in 70% ethanol. Lungs were then processed in a Leica ASP 300 Tissue Processor (Leica Biosystems) before embedding in paraffin wax, and 5 μ m thick sections were cut with a Leica RM2255 Rotary Microtome (Leica Biosystems) and mounted on Superfrost slides (Thermo Fisher Scientific).

To assess airway mucus, Alcian blue–periodic acid–Schiff staining was used. Slides were rehydrated using a Leica autostainer. Slides were then stained with Alcian blue (Sigma) for 15 minutes, 1% periodic acid (Sigma) for 5 minutes, Schiff reagent (Sigma) for 10 minutes, and hematoxylin (Sigma) and 5% acetic acid (Sigma) for 30 seconds. Between each step, slides were washed in distilled water. After staining, all slides were dehydrated and mounted using a Leica autostainer and Leica CV5030 coverslipper. A Panoramic250 slide scanner (3D Histec) was used to obtain images.

Mucus area and epithelial thickness were assessed by an in-house macro. Briefly, a manual line was drawn around the epithelial basement membrane to demarcate an airway. Color thresholding was then used to distinguish between epithelia and mucus (darker purple), with both the area of mucus and the epithelia extracted. The area of mucus was normalized by dividing by the total area of the measured airway. The average thickness of the epithelia per airway was calculated. A median (range) of 9 (5–17) airways per individual mouse was used, with the median mucus area and epithelial thickness for each mouse plotted.

Statistical analysis

For all figures, to compare between groups, mixed linear models were fitted by RStudio (R Core Team) and the 'lme4' package.⁴² To account for random variation, experimental day




FIG 1. PFA-killed spores are unable to induce fungal allergic airway inflammation. **A**, C57BL/6 mice were exposed to 6 doses of live spores (A1160), PFA-killed spores (A1160) (0.4×10^6 per dose), or PBS intranasally on indicated days and tissues collected 24 hours after sixth dose (day 12). **B**, Numbers of different cell populations isolated from BAL fluid of *Af* or PBS exposed mice were assessed by flow cytometry. **C**, Flow cytometry plots show $CD4^+$ T-cell intracellular cytokine production after *ex vivo* stimulation with PMA/ionomycin of lung cells from *Af* or PBS exposed mice. Data were combined from 2 independent experiments ($n = 7-8$ per group). Each data point is 1 individual mouse. Linear mixed effect modeling applied, with experimental repeat as random effect variable; to compare multiple groups, a *post hoc* Tukey HSD test was used. * $P < .05$, ** $P < .01$, *** $P < .001$.

was designated a random effect variable, with time point or genotype as fixed effect variables. To compare multiple groups, a *post hoc* Tukey HSD test conducted by the ‘multcomp’ package.⁴³ For Fig E5, available in the Online Repository available at www.jacionline.org, GraphPad Prism v8.0 (GraphPad Software) was used, with multiple comparisons testing applied after fitting a mixed model using a compound symmetry covariance matrix and restricted maximum likelihood. Bar charts show means and standard errors of the mean.

RESULTS

Af spore viability is required for induction of fungal allergic airway inflammation

To determine the requirement for *Af* viability in mediating early immune sensitization events, we used a murine model of fungal allergic airway inflammation^{19,44} that involved administering repeated doses (4×10^5) of live or PFA-killed spores via intranasal transfer (Fig 1, A). Our prior work has demonstrated that this fungal allergic response is dependent on DCs, with repeat spore dosing triggering expansion and activation of certain DC subsets in the lung and draining lymph nodes.¹⁹ As expected,

24 hours after $6 \times Af$ doses (day 12), we found that mice that received live spores had a significant influx of granulocytes and lymphoid cells in the lung airway (via analysis of cells isolated from BAL fluid) (Fig 1, B). This was also accompanied by markedly increased type 2 (expressing IL-4, IL-5, and IL-13) and type 17 (expressing IL-17) $CD4^+$ T cells in the lung (Fig 1, C), confirming previous reports that repeat intranasally dosing with live *Af* spores induces hallmarks of allergic airway inflammation.⁴⁴ Strikingly, we found that the response in mice that received PFA-killed spores was significantly reduced, and similar to PBS controls (Fig 1, B and C), confirming and extending previous observations⁴⁴ that spore viability is crucial to induce allergic airway inflammation.

A major drawback when using PFA to kill spores is that it can dramatically alter cell wall surface epitopes⁴⁵ as well as halt spore metabolism, both of which could influence the ability of spores to interact with and activate DCs during allergic airway inflammation. Therefore, we utilized the $\Delta pyrG$ *Af* strain (lacking orotidine-5'-monophosphate decarboxylase, an essential enzyme in the pyrimidine biosynthetic pathway), which is viable but unable to develop as a result of disrupted uridine synthesis to investigate whether spore swelling is crucial for *Af* induction of allergic




FIG 2. Fungal allergic airway inflammation in response to *Af* is dramatically reduced when spore swelling is arrested. **A**, C57BL/6 mice were exposed to 6 doses of *Af* spores (A1160), nongerminating Δ pyrG *Af* spores (0.4×10^6 per dose), or PBS intranasally on indicated days and tissues were collected 24 hours after sixth dose (day 12). **B**, Conventional DC subsets 1 and 2 (cDC1, XCR1⁺) and (cDC2, CD11b⁺) in airway (BAL fluid), assessed by flow cytometry. **C**, Immune cell populations in BAL fluid were assessed by flow cytometry. **D**, Secretory factors in BAL fluid were quantified by ELISA. **E**, Representative flow cytometry plots and graphs show lung CD4⁺ T-cell intracellular cytokine staining after *ex vivo* stimulation with PMA/ionomycin. **F**, Lung tissue mRNA expression was assessed by qPCR (normalized against *Gapdh*, a.u.). Data are combined from 2 independent experiments ($n = 8-9$ per group). Each data point is 1 individual mouse. Linear mixed effect modeling applied, with experimental repeat as random effect variable; to compare multiple groups, a *post hoc* Tukey HSD test was used. * $P < .05$, ** $P < .01$, *** $P < .001$.

airway inflammation *in vivo*.³⁸⁻⁴⁰ Mice that were repeatedly exposed to nonswollen Δ pyrG spores showed significantly reduced DC subsets (cDC1 and cDC2), macrophage, granulocyte, and lymphoid cell populations in BAL fluid compared to mice exposed to wild type (WT) (*pyrG*⁺) spores (Fig 2, A-C). Furthermore, nonswollen Δ pyrG spores triggered reduced secretion of mediators associated with allergic inflammation in the airway (measuring resistin-like molecule alpha [RELM α] and chitinase-like protein [Chi3l3] in BAL fluid) compared to WT

spores, which can germinate in the host (Fig 2, D). Surprisingly, despite these differences in inflammatory cell types, nonswelling Δ pyrG spores induced a similar proportion of CD4⁺ T cells to produce type 2 and type 17 cytokines (Fig 2, E), although there was a trend for reduced numbers of these cells. Expression of genes associated with type 2 inflammation (*Retnla*, *Chi3l3*, *I15*) were significantly reduced in the lung tissue of mice that received nonswelling Δ pyrG versus WT spores (Fig 2, F), further supporting that allergic immune responses were impaired.




FIG 3. Fungal allergic airway inflammation-induced lung pathology is reduced when spores are killed or if spore swelling is arrested. C57BL/6 mice were exposed to 6 doses of *Af* spores (A1160), nongerminating $\Delta pyrG$ *Af* spores, PFA-killed spores (A1160) (0.4×10^6 per dose), or PBS intranasally on days 0, 2, 4, 7, 9, and 11, and tissues were collected 24 hours after sixth dose (day 12). **A**, Representative images showing lung sections stained with AB-PAS to assess expansion of mucus-producing goblet cells. **B**, Mucus area in airway epithelia quantified as proportion of overall epithelial area. **C**, Epithelial thickness, measured from basement membrane to lumen, is quantified. Data are combined from 2 independent experiments ($n = 7-8$) per group. Each data point is 1 individual mouse. Linear mixed effect modeling applied, with experimental repeat as random effect variable; to compare multiple groups, a *post hoc* Tukey HSD test was used. * $P < .05$, ** $P < .01$, *** $P < .001$. AB-PAS, Alcian blue-periodic acid-Schiff.

To address whether reduced fungal allergic immunity altered lung tissue inflammation, histologic analysis revealed that WT live spores induced epithelial thickness and goblet cell hyperplasia, as expected (Fig 3). In contrast, both PFA-killed spores and $\Delta pyrG$ spores induced less airway mucus and airway epithelial thickening of the lung tissue (Fig 3, A and B). In summary, these results show that live spores that are incapable of isotropic growth have a much-reduced capacity to trigger fungal allergic airway inflammation.

At least 3 hours of isotropic growth is essential for spores to elicit BMDCs to mediate fungal allergic airway inflammation

After identifying that spore swelling was essential for *in vivo* *Af* induction of allergic airway inflammation (Figs 2 and 3), we wanted to define the precise time point at which spores were able to activate BMDCs to mediate allergic inflammation. Because *Af* spores are rapidly cleared after inhalation, we suggest that immune responses to early stages of spore swelling may be critical. To identify at which point after breaking dormancy *Af* spores were able to elicit an immune response, we further utilized $\Delta pyrG$ spores with timed addition and then removal of

u/u-supplemented media, to arrest isotropic growth at defined time points (Fig 4, A). We confirmed this was achieved by measuring spore morphogenesis via flow cytometry and microscopy, observing that spore size began to increase at 3 hours of culture, with a significant increase in the proportion of swollen spores at 4 hours (Fig 4, B, and Fig E4). Arrested spores remained viable after the removal of u/u, and they were able to germinate when u/u was reintroduced 24 hours later (Fig E4). These stages of growth-arrested $\Delta pyrG$ spores were then each separately cultured with BMDCs to determine their ability to trigger DC activation (Fig 4, C). We consistently found that 3 hours of swelling was the earliest isotropic growth stage that triggered significant BMDC activation, indicated by increased surface expression of costimulatory molecules (CD86, CD80, and major histocompatibility complex class II [MHC-II]) alongside secretion of proinflammatory cytokines (IL-6, IL-12p40, and TNF) (Fig 4, D and E). As expected, later growth stages (4 and 6 hours) induced the most marked BMDC activation (Fig 4, D and E). In comparison, all spores grown in the absence of u/u, 0-, 1-, or 2-hour spore stages did not trigger BMDC activation (Fig 4, D and E). Our findings using the arrested $\Delta pyrG$ system were later confirmed using PFA-killed spores, preswollen for 4 hours, which were able to induce immune activation in BMDCs (Fig E5).




FIG 4. Aftivation of DCs requires spores to undergo at least 3 hours of isotropic growth. **A**, Δ pyrG spores were incubated in presence or absence of u/u with growth arrested by removal of u/u media at indicated timings (between 0 and 6 hours). **B**, Spore size was determined by flow cytometry. **C**, Growth-arrested Δ pyrG spores were incubated with DCs for 5 hours (MOI 5:1) and DC activation analyzed. **D**, DC expression of costimulatory molecules and MHC-II was analyzed via flow cytometry. **E**, DC cytokine secretion was measured via ELISA. Data were combined from 2 independent experiments ($n = 5$ per group). Each data point is 1 individual DC culture. Linear mixed effect modeling applied, with experimental repeat as random effect variable; to compare multiple groups, *post hoc* Tukey HSD test was used. Statistical comparisons to LPS positive control are not shown. * $P < .05$, ** $P < .01$, *** $P < .001$, **** $P < .0001$. MOI, Multiplicity of infection.




FIG 5. Three hours of isotropic growth is essential for spores to elicit DC ability to mediate fungal allergic airway inflammation. **A**, Arrested Δ *pyrG* spore stages were generated by incubating in presence of u/u, then removed and washed after 0, 2, or 3 hours. These were then cultured with BMDCs for 5 hours before intranasal transfer of 50,000 DCs into C57BL/6 mice. Mice were challenged intranasally at days 11 and 12 with 0.4×10^6 live CEA10 *Af* spores. **B**, Immune cell populations in BAL fluid were assessed by flow cytometry. Number of different cell populations isolated from BAL fluid of DC-sensitized mice was assessed by flow cytometry. **C**, Representative flow cytometry plots of CD44⁺CD4⁺ T cells in BAL fluid. **D**, Secretory factors in BAL fluid were quantified by ELISA. **E**, Representative flow cytometry plots and graphs show lung CD4⁺ T-cell intracellular cytokine staining after *ex vivo* stimulation with PMA/ionomycin. Data were combined from 2 independent experiments ($n = 6$ per group). Each data point is 1 individual mouse. Linear mixed effect modeling applied, with experimental repeat as random effect variable; to compare multiple groups, *post hoc* Tukey HSD test was used. * $P < .05$, ** $P < .01$, *** $P < .001$, **** $P < .0001$.

Importantly, incubation of BMDCs with live spores for 5 hours only induced minor BMDC immune activation, likely because more immunogenic stages (3+ hours) had reduced time to interact with the BMDCs (Fig E5). This highlights the importance of using growth-arrested *Af* to allow sufficient time for immune activation by each spore morphotype. Taken together, by utilizing the A1160 Δ *pyrG* strain and a novel approach of timed addition and removal of u/u, we have pinpointed the earliest morphotype spore stage that is able to trigger BMDC activation.

Having shown that 3 hours of *Af* isotropic growth was sufficient to induce BMDC activation *in vitro*, we wanted to ascertain if these were able to mediate allergic airway inflammation *in vivo*. To test this, we adapted a BMDC adoptive transfer model that we have used previously,⁴⁰ whereby BMDCs previously exposed for 0, 2, or 3 hours to arrested Δ *pyrG* spores were administered intranasally to naïve recipient mice, followed by 2 further

intranasal challenge doses of live *Af* spores (days 11 and 12 after BMDC sensitization) (Fig 5, A). Only mice that were sensitized to BMDCs pulsed with 3-hour spores displayed increased cell recruitment to the airways, with significantly increased granulocytes (neutrophils and eosinophils) and lymphocyte (natural killer cells, CD4⁺ and CD8⁺ T cells, and $\gamma\delta$ T cells) populations in BAL fluid compared to mice sensitized with BMDCs that had been cultured in media alone (Fig 5, B). In addition, there was also a significant increase in the number of activated CD4⁺ T cells (CD44⁺) (Fig 5, C), as well as secretory factors associated with allergic inflammation (RELm α and Ym1) in BAL fluid (Fig 5, D). Adoptively transferred BMDCs that had been cultured with 3-hour spores were able to induce significant expansion of type 2 cytokine-expressing CD4⁺ T cells (Fig 5, E). In contrast, mice that received BMDCs that had been exposed to 0- or 2-hour spores showed no evidence of fungal allergic




FIG 6. Itraconazole reduces swelling of spores and ability to activate DCs. **A**, Δ pyrG spores were incubated with u/u-containing media in presence or absence of itraconazole (itr); then growth was arrested by removal of u/u media at 0 or 4 hours. **B**, Spore size was determined by flow cytometry. **C**, Growth-arrested and itraconazole-treated Δ pyrG spores were incubated with DCs for 5 hours (MOI 5:1) and DC activation analyzed. **D**, DC expression of costimulatory molecules and MHC-II was analyzed via flow cytometry. **E**, DC cytokine secretion was measured via ELISA. Data were combined from 2 independent experiments ($n = 6$ per group). Each data point is 1 individual DC culture. Linear mixed effect modeling applied, with experimental repeat as random effect variable; to compare multiple groups, *post hoc* Tukey HSD test was used. Statistical comparisons to LPS-positive control are not shown. * $P < .05$, ** $P < .01$, *** $P < .001$, **** $P < .0001$. MOI, Multiplicity of infection.

inflammation (Fig 5, E). However, these did not trigger IL-17 immune responses (Fig 5, E). In summary, these data show that BMDC induction of fungal allergic airway inflammation against *Af* is dependent on their recognition of a defined spore morphotype that requires at least 3 hours of growth to become immunogenic.

Treatment of *Af* with antifungal agents partially reduces spore capacity to activate ability of BMDC to induce allergic airway inflammation

Although it has been reported that antifungal therapies (including azole drugs such as itraconazole) can be a successful

treatment strategy for patients with severe fungal asthma,^{46–48} the mechanisms that underpin this are poorly understood. Therefore, we reasoned that one partial explanation may be that antifungal treatment could interfere with early spore swelling and thus reduce their capability to activate BMDCs to induce allergic airway inflammation. To our knowledge, few studies have assessed how antifungal drugs affect early stages of *Af* spore swelling. We found that incubating Δ pyrG *Af* in the presence of itraconazole (and u/u) for 4 hours significantly reduced spore swelling (Fig 6, A and B). To test whether this affected *Af* immunogenicity, spores were grown in the presence or absence of itraconazole, washed extensively to remove itraconazole, and then cultured with BMDC (Fig 6, A–C). Itraconazole-treated 4-hour




FIG 7. Spores treated with itraconazole partially reduced their capacity to activate DC ability to induce fungal allergic airway inflammation. **A**, Δ pyrG spores were incubated with u/u-containing media in presence or absence of itraconazole (itr); then growth was arrested by removal of u/u media at 0 or 4 hours. These were then incubated with DCs for 5 hours before intranasal transfer of 50,000 DCs into C57BL/6 mice. Mice were challenged intranasally at days 11 and 12 with 0.4×10^6 live CEA10 *Af* spores. **B**, Immune cell populations in BAL fluid of DC-sensitized mice were assessed by flow cytometry. Number of different cell populations isolated from BAL fluid of DC-sensitized mice was assessed by flow cytometry. **C**, Representative flow cytometry plots of CD44⁺ CD4⁺ T cells in BAL fluid. **D** and **E**, Secretory factors in BAL fluid were quantified by ELISA. **F**, Lung sections were stained with AB-PAS to assess expansion of mucus-producing goblet cells, with mucus area in airway epithelia quantified as proportion of overall epithelial area. Data are combined from 2 independent experiments ($n = 6$ –10 per group). Each data point is 1 individual mouse. Linear mixed effect modeling was applied, with experimental repeat as random effect variable; to compare multiple groups, *post hoc* Tukey HSD test was used. * $P < .05$, ** $P < .01$, *** $P < .001$, **** $P < .0001$. AB-PAS, Alcian blue–periodic acid–Schiff.

spores showed a significantly impaired ability to activate BMDCs compared to 4-hour spores that had not been treated with itraconazole in terms of induction of surface expression of costimulatory molecules (CD40, CD80, CD86, and MHC-II) and production of proinflammatory cytokines (IL-6, IL-12p40, and TNF) (Fig 6, D and E). However, while itraconazole-treated 4-hour arrested spores were less proficient at activating BMDCs than untreated 4-hour spores, the response detected was still significantly above the activation state of BMDCs cultured with

0-hour spores. Together, these data indicate that *Af* treatment with azole-based drugs can reduce, but not eliminate, the ability of early swollen spore stages to activate BMDCs *in vitro*.

To test if itraconazole treatment also affected the ability of early swollen *Af* spores to influence BMDC induction of fungal allergic airway inflammation, we transferred BMDCs that had been cultured with 0- or 4-hour arrested spores germinated in the presence or absence of itraconazole into the airways of naïve recipient mice (Fig 7, A). BMDCs that had been activated with

either 4-hour spores or itraconazole-treated 4-hour spores promoted similar levels of cellular inflammation in the airways of recipient mice (Fig 7, B), with a trend that BMDCs activated with itraconazole-treated spores induced less marked eosinophilia. Notably, BMDCs that had been cultured with itraconazole-treated spores did display significantly reduced ability to activate CD4⁺ T cells *in vivo*, particularly in terms of number of activated CD44⁺CD4⁺ T cells recruited to the airways (Fig 7, B and C). Analysis of mediators in BAL fluid revealed that while 4-hour spore-treated BMDCs could induce *in vivo* secretion of RELM α and Ym1 (likely from resident macrophages), this was not significantly reduced with itraconazole treatment (Fig 7, D). When specifically focusing on IL-12p40 and IL-6, in line with our *in vitro* results (Fig 6, E), we saw a tendency for increased airway IL-6 and IL-12p40 in the 4-hour DC group, which tended to reduce in the 4-hour plus itraconazole group (Fig 7, E). A similar pattern was observed with airway mucus, with a tendency for the most mucus area in the 4-hour DC group (Fig 7, F). Taken together, these data show that itraconazole treatment of *Af* spores disrupts their morphotype transition while tending to make them less effective at activating BMDCs to induce allergic airway inflammation.

DISCUSSION

Using novel approaches to track and arrest differing stages of *Af* germination, we have identified a defined timepoint during isotropic spore growth which activates DCs to elicit robust allergic inflammation after *Af* exposure. We have further identified that itraconazole, a crucial antifungal drug, tends to limit this process, thereby reducing the ability of *Af* to elicit DC induction of allergic airway inflammation.

Sensitization to *Af* triggers and exacerbates the allergic airway inflammation that underpins asthma.^{19,31,44} Few studies, however, have dissected the relative importance of early spore growth in triggering innate immune cells to elicit allergic inflammation. Previous studies have proposed that germination, with the breakdown of the hydrophobic rodlet/melanin layer that masks *Af* cell wall pathogen-associated molecular patterns—for example, β -glucan—is crucial to trigger innate cell activation and allergic inflammation.^{28,31} These findings were largely achieved using spore-killing approaches (eg, PFA), and we confirm similar results, showing that PFA-killed *Af* is less able to elicit allergic airway inflammation. However, PFA killing alters surface epitopes, disrupts spore metabolism, and significantly changes dispersal patterns in the airways, all of which may have contributed to the observed defect independent of disruption of spore germination.^{45,49} Our study overcomes these limitations; by utilizing a mutant strain (Δ *pyrG*)^{38,39} that requires exogenous u/u to grow, we demonstrated a requirement for spore development to promote allergic airway inflammation. Surprisingly, Δ *pyrG* spores did induce minor lung inflammation and goblet cell expansion greater than the response elicited by PFA-killed spores, albeit to a much lower extent than responses caused by WT spores. Previous reports have shown that viable ungerminated spores are partially active, with low-level transcriptional activity.⁵⁰ The mechanism or mechanisms by which viable ungerminated spores can trigger low levels of inflammation is an important question for future work. In summary, these results highlight that breaking of dormancy and isotropic growth is crucial for promotion of allergic airway inflammation.

We have recently elucidated the role of DCs in mediating allergic inflammation in response to *Af* spores.¹⁹ Therefore, having established a requirement for spore swelling, we wanted to pinpoint if there was a precise *Af* morphotype that triggers DCs to induce allergic inflammation. Via novel use of the Δ *pyrG* *Af* strain with timed removal of u/u (Fig 3), we discovered that the 3-hour viable early swollen *Af* spore stage is the earliest stage able to induce DC activation and allergic priming (Figs 3 and 4). To our knowledge, we are the first to demonstrate that an early-stage spore morphotype is crucial to generate allergic inflammation—earlier than previously thought, as it is before the development of germings and hyphal extension. Indeed, prior research on fungal allergy has focused predominantly on *Af* extracts and/or components revealed/secreted at the germling or hyphal stages that are not exposed at the spore stage. For example, research into β -glucan, a key mediator of antifungal responses and allergic inflammation, has focused on its exposure at the germling stage at $\sim$ 7 hours, but recent work has suggested potential earlier expression.^{31,51} Furthermore, many of the previously characterized *Af* allergens are expressed/secreted predominantly at the hyphal stage, such as Asp f 5 and Asp f 13,^{34,35,52,53} suggesting these may not be involved in initial spore mediated sensitization. Therefore, we are unaware of crucial mediators expressed by spores that trigger allergic disease. Recent evidence has emerged that the spore wall is more dynamic than previously thought, with both resting and swollen spores (at 5 hours) expressing over 140 surface proteins, including low levels of β -glucan, and earlier (2 hours) swollen *Af* spores able to secrete immunomodulatory proteases.^{36,51,54} Our novel approach of timed removal of u/u to arrest Δ *pyrG* spore growth could be crucial to elucidate immunogenic factors expressed at early stages of spore development, which have the potential to interact with host immune cells.

To ascertain the potential of *Af* spores to elicit allergy, we primarily focused on their interactions with DCs because of their well-established role bridging innate and adaptive immunity to initiate allergic airway responses.^{14,16} Determining the ability of DCs to mediate type 2 inflammation *in vitro* is challenging because the mechanism(s) they utilize to mediate these responses are unclear.⁵⁵ However, 3-hour spores increased DC expression of costimulatory molecules (CD80 and CD86) and proinflammatory cytokines prevalent during allergic inflammation.⁵⁶⁻⁵⁹ To confirm that these changes resulted in allergic inflammation, we utilized a DC transfer approach, which we have used previously with other stimuli.^{60,61} This showed 3-hour-spore pulsed DCs induced a type 2 inflammatory response (including influxes of eosinophils and type 2 cytokine-expressing CD4⁺ T cells) (Fig 4) similar to responses observed after repeated intranasal *Af* exposure and demonstrates the importance of *in vivo* testing when confirming capability of DCs to induce type 2 polarization. We did not observe induction of IL-17 by 3-hour-spore pulsed DCs, supporting a hypothesis that IL-17 induction occurs via different pathways that may include other DC subsets¹⁹ and/or signals triggered by fungal mediated damage of airway (eg, epithelium).³³ The precise process that DCs utilize to recognize spores and trigger downstream inflammation is unclear. However, *Af* and allergens such as house dust mite have been shown to signal via both Toll-like receptor and C-type lectin receptors on innate immune cells.⁶²⁻⁶⁴ Defining the precise spore morphotype that elicits DCs to mediate

allergic inflammation provides an important platform to address this crucial question.

Despite evidence that antifungal drugs can be utilized as effective treatment strategies for severe asthma with fungal sensitization and allergic bronchopulmonary aspergillosis patients, the fungal morphotypes targeted in this intervention are unclear.⁴⁶⁻⁴⁸ Here we identify a possible mechanism, one in which antifungal treatment partially inhibits the early stages of spore swelling, which we have shown to be critical to activate DCs to prime fungal airway allergy (Fig 6). A limitation of our work is reduced applicability to males, as only female mice were used. Nonetheless, our results could explain the efficacy observed in clinical trials of itraconazole in severe asthma independent of fungal colonization status, as our data indicate that spores would only need to remain in the airways for 3 hours to induce allergic inflammation.⁶⁵ Furthermore, our data highlight that itraconazole treatment alone is not sufficient to completely arrest spore swelling and inhibit their ability to induce DC-mediated allergic airway inflammation or goblet cell expansion. Recent work has identified that combination therapy of antifungal agents can be more effective in treatment of disease and reduce the threat of drug resistance emerging.⁶⁶ Therefore, with more therapeutics needed, high-throughput screening of compound libraries to identify candidates able to inhibit early spore swelling may be an effective strategy for discovery of novel drugs to treat fungal allergy.⁶⁷

Taken together, our work has highlighted the critical importance of the early stages of spore swelling in promoting allergic airway inflammation, with understanding the allergenic factors in 3-hour spores a key angle for future research. Additionally, our work extends understanding of the potential mechanism of action of a currently used drug (itraconazole) in fungal asthma while also recommending that future therapeutics should be assessed for their ability to inhibit isotropic growth. Although our focus has been on *Af*, our findings are relevant for other allergenic filamentous fungi, including other *Aspergillus* species such as *A flavus* and *A niger*, with *Aspergillus* sensitization associated with increased asthma severity.⁶⁸⁻⁷¹ Whether our findings are translatable to other fungal species associated with allergic disease is unknown and is a key topic for future research.

DISCLOSURE STATEMENT

E.L.H. was supported by a Biotechnology and Biological Sciences Research Council CASE studentship (with GSK) (BB/P504543/1) and A.S.M. by Lydia Becker core funding and the Medical Research Council (MRC; MR/W018748/1). P.C.C. was supported with a University of Manchester Dean's Prize Early Career Research Fellowship Springboard Award (Academy of Medical Sciences, grant SBF002/1076). G.V., J.F.S., D.C., and P.C.C. were supported by Royal Society and Wellcome Trust Sir Henry Dale Fellowship (218550/Z/19/Z, awarded to P.C.C.). G.V., J.F.S., D.C., E.H., G.D.B., W.H., and P.C.C. acknowledge funding from the MRC Centre for Medical Mycology at the University of Exeter (MR/N006364/2 and MR/V033417/1), the National Institute for Health Research (NIHR) Exeter Biomedical Research Centre (NIHR203320), and the MRC Doctoral Training Grant MR/P501995/2. G.D.B. acknowledges funding from the Wellcome Trust (217163). S.G. was cofunded by the NIHR Manchester Biomedical Research Centre (www.manchesterbrc.nihr.ac.uk/) and a National Centre for the Replacement, Refinement & Reduction of Animals in Research (NC3Rs, www.nc3rs.org.uk/) Training Fellowship (NC/P002390/1), and by the Fungal Infection Trust and the Dowager Countess Eleanor Peel Trust.

uk/) Training Fellowship (NC/P002390/1), and by the Fungal Infection Trust and the Dowager Countess Eleanor Peel Trust.

Disclosure of potential conflict of interest: Individuals based at the Lydia Becker Institute received funding from GSK. These authors (E. L. Houlder, A. S. MacDonald, and P. C. Cook) declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. In the last 5 years, S. Gago has received research funds from Pfizer and honoraria for talks from Gilead outside the current study. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. The rest of the authors declare that they have no relevant conflicts of interest.

We thank current and previous members of the Manchester Fungal Infection Group, the Lydia Becker Institute, MacDonald's laboratory (University of Manchester), and the MRC Centre for Medical Mycology (University of Exeter) for scientific discussions and some experimental assistance, as well as the University of Manchester and Exeter flow cytometry facilities. Additional work may have been undertaken by the University of Exeter Biological Services Unit.

Key messages

- We have pinpointed the precise stage of *Af* development when germinating spores are capable of activating DCs to mediate downstream allergic airway inflammation.
- Antifungals (itraconazole) tended to reduce the potential of *Af* spores to stimulate allergic responses, highlighting a potential mechanism by which antifungal treatment might help to prevent the development of fungal allergy.

REFERENCES

1. Denning DW, O'Driscoll BR, Hogaboam CM, Bowyer P, Niven RM. The link between fungi and severe asthma: a summary of the evidence. *Eur Respir J* 2006;27:615-26.
2. Li E, Knight JM, Wu Y, Luong A, Rodriguez A, Kheradmand F, et al. Airway mycosis in allergic airway disease. In: Alt F, editor. *Advances in immunology*, volume 142. Amsterdam: Elsevier; 2019. pp. 85-140; <https://doi.org/10.1016/b.s.ai.2019.05.002>.
3. Brown GD, Ballou ER, Bates S, Bignell EM, Borman AM, Brand AC, et al. The pathobiology of human fungal infections. *Nat Rev Microbiol* 2024.
4. Denning DW. Global incidence and mortality of severe fungal disease. *Lancet Infect Dis* 2024;24:e428-38.
5. Bongomin F, Gago S, Oladele RO, Denning DW. Global and multi-national prevalence of fungal diseases—estimate precision. *J Fungi (Basel)* 2017;3:E57.
6. Goh KJ, Yli ACA, Lapperre TS, Chan AKW, Chew FT, Chotirmall SH, et al. Sensitization to *Aspergillus* species is associated with frequent exacerbations in severe asthma. *J Asthma Allergy* 2017;10:131-40.
7. Medrek SK, Kao CC, Yang DH, Hanania NA, Parulekar AD. Fungal sensitization is associated with increased risk of life-threatening asthma. *J Allergy Clin Immunol Pract* 2017;5:1025-31.e2.
8. Denning DW, Pashley C, Hartl D, Wardlaw A, Godet C, Giacco S, et al. Fungal allergy in asthma—state of the art and research needs. *Clin Transl Allergy* 2014;4:14.
9. Fraczek MG, Chishimba L, Niven RM, Bromley M, Simpson A, Smyth L, et al. Corticosteroid treatment is associated with increased filamentous fungal burden in allergic fungal disease. *J Allergy Clin Immunol* 2018;142:407-14.
10. Li E, Tsai C, Maskatia ZK, Kakkar E, Porter P, Rossen RD, et al. Benefits of antifungal therapy in asthma patients with airway mycosis: a retrospective cohort analysis. *Immun Inflamm Dis* 2018;6:264-75.
11. Patterson TF, Thompson GR, Denning DW, Fishman JA, Hadley S, Herbrecht R, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. *Clin Infect Dis* 2016;63:e1-60.

12. Amich J, Mokhtari Z, Strobel M, Vialetto E, Sheta D, Yu Y, et al. Three-dimensional light sheet fluorescence microscopy of lungs to dissect local host immune-*Aspergillus fumigatus* interactions. *mBio* 2020;11:e02752-19.
13. Bhatia S, Fei M, Yarlagadda M, Qi Z, Akira S, Saijo S, et al. Rapid host defense against *Aspergillus fumigatus* involves alveolar macrophages with a predominance of alternatively activated phenotype. *PLoS One* 2011;6:e15943.
14. Furlong-Silva J, Cook PC. Fungal-mediated lung allergic airway disease: the critical role of macrophages and dendritic cells. *PLoS Pathog* 2022;18:e1010608.
15. Kuek LE, Lee RJ. First contact: the role of respiratory cilia in host-pathogen interactions in the airways. *Am J Physiol Lung Cell Mol Physiol* 2020;319:L603-19.
16. Bozza S, Gaziano R, Spreca A, Bacci A, Montagnoli C, Francesco P di, et al. Dendritic cells transport conidia and hyphae of *Aspergillus fumigatus* from the airways to the draining lymph nodes and initiate disparate Th responses to the fungus. *J Immunol* 2002;168:1362-71.
17. Lambrecht BN, Veerman MD, Coyle AJ, Gutierrez-Ramos JC, Thielemans K, Pauwels RA. Myeloid dendritic cells induce Th2 responses to inhaled antigen, leading to eosinophilic airway inflammation. *J Clin Invest* 2000;106:551-9.
18. van Helden MJ, Lambrecht BN. Dendritic cells in asthma. *Curr Opin Immunol* 2013;25:745-54.
19. Cook PC, Brown SL, Houlder EL, Baker S, Svedberg FR, Howell G, et al. Mgl²⁺ cDC2s coordinate fungal allergic airway type 2, but not type 17, inflammation. *bioRxiv* November 25, 2023; <https://doi.org/10.1101/2023.11.24.568263>.
20. Hammad H, Lambrecht BN. The basic immunology of asthma. *Cell* 2021;184:1469-85.
21. Latgé JP. *Aspergillus fumigatus* and aspergillosis. *Clin Microbiol Rev* 1999;12:310-50.
22. Latgé JP, Chamilos G. *Aspergillus fumigatus* and aspergillosis in 2019. *Clin Microbiol Rev* 2019;33:e00140-18.
23. Aimananda V, Bayry J, Bozza S, Kniemeyer O, Perruccio K, Elluru SR, et al. Surface hydrophobin prevents immune recognition of airborne fungal spores. *Nature* 2009;460(7259):1117-21.
24. Aimananda V, Latgé JP. Fungal hydrophobins form a sheath preventing immune recognition of airborne conidia. *Virulence* 2010;1:185-7.
25. Beauvais A, Bozza S, Kniemeyer O, Formosa C, Balloy V, Henry C, et al. Deletion of the α -(1,3)-glucan synthase genes induces a restructuring of the conidial cell wall responsible for the avirulence of *Aspergillus fumigatus*. *PLoS Pathog* 2013;9:e1003716.
26. Carrion S de J, Leal SM, Ghannoum MA, Aimananda V, Latgé JP, Pearlman E. The RodA hydrophobin on *Aspergillus fumigatus* spores masks dectin-1- and dectin-2-dependent responses and enhances fungal survival *in vivo*. *J Immunol* 2013;191:2581-8.
27. Luther K, Torosantucci A, Brakhage AA, Heesemann J, Ebel F. Phagocytosis of *Aspergillus fumigatus* conidia by murine macrophages involves recognition by the dectin-1 beta-glucan receptor and Toll-like receptor 2. *Cell Microbiol* 2007;9:368-81.
28. Van De Veerdonk FL, Gresnigt MS, Romani L, Netea MG, Latgé JP. *Aspergillus fumigatus* morphology and dynamic host interactions. *Nat Rev Microbiol* 2017;15:661-74.
29. Brown GD, Gordon S. A new receptor for β -glucans. *Nature* 2001;413(6851):36-7.
30. Dambua IM, Levitz SM, Netea MG, Brown GD. Fungal recognition and host defense mechanisms. *Microbiol Spectr* 2017;5(4).
31. Hohl TM, Van Epps HL, Rivera A, Morgan LA, Chen PL, Feldmesser M, et al. *Aspergillus fumigatus* triggers inflammatory responses by stage-specific β -glucan display. *PLoS Pathog* 2005;1(3):e30.
32. Porter P, Susarla SC, Polikepahad S, Qian Y, Hampton J, Kiss A, et al. Link between allergic asthma and airway mucosal infection suggested by proteinase-secreting household fungi. *Mucosal Immunol* 2009;2:504-17.
33. Balenga NA, Klichinsky M, Xie Z, Chan EC, Zhao M, Jude J, et al. A fungal protease allergen provokes airway hyper-responsiveness in asthma. *Nat Commun* 2015;6:6763.
34. Namvar S, Warn P, Farnell E, Bromley M, Fraczek M, Bowyer P, et al. *Aspergillus fumigatus* proteases, Asp f 5 and Asp f 13, are essential for airway inflammation and remodelling in a murine inhalation model. *Clin Exp Allergy* 2015;45:982-93.
35. Redes JL, Basu T, Ram-Mohan S, Ghosh CC, Chan EC, Sek AC, et al. *Aspergillus fumigatus*-secreted alkaline protease 1 mediates airways hyperresponsiveness in severe asthma. *Immunohorizons* 2019;3:368-77.
36. Blango MG, Pschibul A, Rivieccio F, Krüger T, Rafiq M, Jia LJ, et al. Dynamic surface proteomes of allergenic fungal conidia. *J Proteome Res* 2020;19:2092-104.
37. Ortiz SC, Pennington K, Thomson DD, Bertuzzi M. Novel insights into *Aspergillus fumigatus* pathogenesis and host response from state-of-the-art imaging of host-pathogen interactions during infection. *J Fungi (Basel)* 2022;8:264.
38. d'Enfert C. Selection of multiple disruption events in *Aspergillus fumigatus* using the orotidine-5'-decarboxylase gene, pyrG, as a unique transformation marker. *Curr Genet* 1996;30:76-82.
39. da Silva Ferreira ME, Kress MRVZ, Savoldi M, Goldman MHS, Härtl A, Heinekamp T, et al. The akuBKU80 mutant deficient for nonhomologous end joining is a powerful tool for analyzing pathogenicity in *Aspergillus fumigatus*. *Eukaryot Cell* 2006;5:207-11.
40. MacDonald D, Thomson DD, Johns A, Contreras Valenzuela A, Gilson JM, Lord KM, et al. Inducible cell fusion permits use of competitive fitness profiling in the human pathogenic fungus *Aspergillus fumigatus*. *Antimicrob Agents Chemother* 2018;63:e01615-8. Erratum in: *Antimicrob Agents Chemother* 2019;63:e00706-19.
41. Monod M, Paris S, Sarfati J, Jatton-Ogay K, Ave P, Latgé JP. Virulence of alkaline protease-deficient mutants of *Aspergillus fumigatus*. *FEMS Microbiol Lett* 1993;106:39-46.
42. Bates D, Mächler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme4. *J Stat Softw* 2015;67:1-48.
43. Hothorn T, Bretz F, Westfall P. Simultaneous inference in general parametric models. *Biom J* 2008;50:346-63.
44. Porter PC, Roberts L, Fields A, Knight M, Qian Y, Delclos GL, et al. Necessary and sufficient role for T helper cells to prevent fungal dissemination in allergic lung disease. *Infect Immun* 2011;79:4459-71.
45. Dapson R. Macromolecular changes caused by formalin fixation and antigen retrieval. *Biotech Histochem* 2007;82:133-40.
46. Denning DW, O'Driscoll BR, Powell G, Chew F, Atherton GT, Vyas A, et al. Randomized controlled trial of oral antifungal treatment for severe asthma with fungal sensitization. *Am J Respir Crit Care Med* 2009;179:11-8.
47. Stevens DA, Schwartz HJ, Lee JY, Moskovitz BL, Jerome DC, Catanzaro A, et al. A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. *N Engl J Med* 2000;342:756-62.
48. Wark PAB, Hensley MJ, Saltos N, Boyle MJ, Toneguzzi RC, Epid GDC, et al. Anti-inflammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis: a randomized controlled trial. *J Allergy Clin Immunol* 2003;111:952-7.
49. Baltussen TJH, Zoll J, Verweij PE, Melchers WJG. Molecular mechanisms of conidial germination in *Aspergillus* spp. *Microbiol Mol Biol Rev* 2019;84:e00049-19.
50. Wang F, Sethiya P, Hu X, Guo S, Chen Y, Li A, et al. Transcription in fungal conidia before dormancy produces phenotypically variable conidia that maximize survival in different environments. *Nat Microbiol* 2021;6:1066-81.
51. Hatinguais R, Kay M, Salazar F, Conn DP, Williams DL, Cook PC, et al. Development of negative controls for FcC-type lectin receptor probes. *Microbiol Spectr* 2023;11:e0113523.
52. Behnsen J, Lessing F, Schindler S, Wartenberg D, Jacobsen ID, Thoen M, et al. Secreted *Aspergillus fumigatus* protease Alp1 degrades human complement proteins C3, C4, and C5. *Infect Immun* 2010;78:3585-94.
53. Tomee JFC, Wierenga ATJ, Hiemstra PS, Kauffman HF. Proteases from *Aspergillus fumigatus* induce release of proinflammatory cytokines and cell detachment in airway epithelial cell lines. *J Infect Dis* 1997;176:300-3.
54. Shende R, Wong SSW, Rapole S, Beau R, Ibrahim-Granet O, Monod M, et al. *Aspergillus fumigatus* conidial metalloprotease Mep1p cleaves host complement proteins. *J Biol Chem* 2018;293:15538-55.
55. Lamielle O, Mayer JU, Munoz-Erazo L, Ronchese F. Dendritic cells in Th2 immune responses and allergic sensitization. *Immunol Cell Biol* 2020;98:807-18.
56. Alnahas S, Hagner S, Raifer H, Kilic A, Gasteiger G, Mutters R, et al. IL-17 and TNF- α are key mediators of *Moraxella catarrhalis* triggered exacerbation of allergic airway inflammation. *Front Immunol* 2017;8:1562.
57. Gubernatorova EO, Gorshkova EA, Namakanova OA, Zvartsev RV, Hidalgo J, Drutskaya MS, et al. Non-redundant functions of IL-6 produced by macrophages and dendritic cells in allergic airway inflammation. *Front Immunol* 2018;9:2718.
58. Lin YL, Chen SH, Wang JY. Critical role of IL-6 in dendritic cell-induced allergic inflammation of asthma. *J Mol Med (Berl)* 2016;94:51-9.
59. Van Rijt LS, Vos N, Willart M, KleinJan A, Coyle AJ, Hoogsteden HC, et al. Essential role of dendritic cell CD80/CD86 costimulation in the induction, but not reactivation, of Th₂ effector responses in a mouse model of asthma. *J Allergy Clin Immunol* 2004;114:166-73.
60. Cook PC, Owen H, Deaton AM, Borger JG, Brown SL, Clouaire T, et al. A dominant role for the methyl-CpG-binding protein Mbd2 in controlling Th2 induction by dendritic cells. *Nat Commun* 2015;6:6920.
61. Webb LM, Lundie RJ, Borger JG, Brown SL, Connor LM, Cartwright AN, et al. Type I interferon is required for T helper (Th) 2 induction by dendritic cells. *EMBO J* 2017;36:2404-18.
62. Ito T, Hirose K, Norimoto A, Tamachi T, Yokota M, Saku A, et al. Dectin-1 plays an important role in house dust mite-induced allergic airway inflammation through the activation of CD11b⁺ dendritic cells. *J Immunol* 2017;198:61-70.
63. Salazar F, Ghaemmaghami A. Allergen recognition by innate immune cells: critical role of dendritic and epithelial cells. *Front Immunol* 2013;4:356.

64. Schreibelt G, Klinkenberg LJJ, Cruz LJ, Tacke PJ, Tel J, Kreutz M, et al. The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-)presentation by human blood BDCA3⁺ myeloid dendritic cells. *Blood* 2012;119:2284-92.
65. Mirsadraee M, Dehghan S, Ghaffari S, Mirsadraee N. Long-term effect of antifungal therapy for the treatment of severe resistant asthma: an active comparator clinical trial. *Curr Med Mycol* 2019;5:1-7.
66. Fisher MC, Alastruey-Izquierdo A, Berman J, Bicanic T, Bignell EM, Bowyer P, et al. Tackling the emerging threat of antifungal resistance to human health. *Nat Rev Microbiol* 2022;20:557-71.
67. Wall G, Lopez-Ribot JL. Screening repurposing libraries for identification of drugs with novel antifungal activity. *Antimicrobial Agents and Chemotherapy* 2020;64:e00924-20.
68. Agarwal R, Gupta D. Severe asthma and fungi: current evidence. *Med Mycol* 2011;49(suppl 1):S150-7.
69. Backman H, Jansson SA, Stridsman C, Eriksson B, Hedman L, Eklund BM, et al. Severe asthma—a population study perspective. *Clin Exp Allergy* 2019;49:819-28.
70. Kwizera R, Musaaizi J, Meya DB, Worodria W, Bwanga F, Kajumbula H, et al. Burden of fungal asthma in Africa: a systematic review and meta-analysis. *PLoS One* 2019;14:e0216568.
71. Sehgal IS, Choudhary H, Dhoooria S, Aggarwal AN, Bansal S, Garg M, et al. Prevalence of sensitization to *Aspergillus flavus* in patients with allergic bronchopulmonary aspergillosis. *Med Mycol* 2019;57:270-6.